We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Alzheimer’s Drug Significantly Helped Slow Patient Decline, Study Finds
Eli Lilly’s Alzheimer’s Drug Significantly Helped Slow Patient Decline, Study Finds
A phase 2 trial of Eli Lilly’s investigational Alzheimer’s drug donanemab demonstrated a “significant slowing of decline” in early Alzheimer’s patients who exhibited symptoms, the company revealed Monday.